Skip Navigation



JAC Advance Access published online on January 14, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg085
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/439    most recent
dkg085v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gatta, L.
Right arrow Articles by Vaira, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gatta, L.
Right arrow Articles by Vaira, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori

Luigi Gatta 1, Federico Perna 1, Natale Figura 2, Chiara Ricci 1, John Holton 3, Luigi D'Anna 4, Mario Miglioli 1, Dino Vaira 1*

1 Department of Internal Medicine and Gastroenterology, University of Bologna, via Massarenti 9, 40138 Bologna, Italy
2 Department of Internal Medicine, Siena, Italy
3 Department of Microbiology, University College, London, UK
4 Military Hospital, Rome, Italy

* Corresponding author. E-mail: vairadin{at}med.unibo.it.

Received 20 June 2002 ; revised 8 August 2002 ; accepted 11 November 2002

Abstract

Objective: Esomeprazole is an enantiomorph of omeprazole, which inhibits gastric acid secretion more effectively than omeprazole. As proton pump inhibitors also exert an antibacterial activity, we aimed to compare esomeprazole and omeprazole for their antimicrobial activity against Helicobacter pylori in vitro.

Methods: We studied 52 H. pylori isolates obtained from gastric biopsies and inoculated onto agar plates containing the acid-converted drugs at different concentrations. The minimal concentrations that inhibited the growth of 50% and 90% of isolates were defined as MIC50 and MIC90.

Results: The MIC50 and MIC90 of esomeprazole were 16 and 32 mg/L; and those of omeprazole were 32 and 64 mg/L. Overall, 63.5% of isolates showed the same susceptibility to both drugs; 17 isolates were two- to 64-fold more susceptible to esomeprazole and two isolates were two-fold more susceptible to omeprazole.

Conclusions: The increased antimicrobial activity in vitro of esomeprazole against H. pylori could contribute to improving the outcome of the eradication treatment of such an infection.

Keywords: Helicobacter pylori, omeprazole, esomeprazole, antimicrobial activity
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.